Letrozole and the IGF-I receptor tyrosine kinase inhibitor NVP-AEW541 combine synergistically in an in vitro model of estrogen-dependent breast cancer proliferation.

被引：0
|
作者：
Hergovich, Lisztwan J.
Pornon, A.
Chen, S.
Pearson, M. A.
Evans, D. B.
机构：
[1] Novartis Inst BioMed Res, Basel, Switzerland
[2] City Hope Natl Med Ctr, Beckman Res Inst, Duarte, CA 91010 USA
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2006年 / 100卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S248 / S248
页数：1
相关论文
共 14 条
  • [1] Combining the selective IGF-1R tyrosine kinase inhibitor NVP-AEW541 with cytostatic agents or trastuzumab in various breast cancer cell lines
    Hartog, Hermien
    Van der Graaf, Winette T. A.
    Van Zweeden, Martine
    Boezen, H. Marike
    Wesseling, Jelle
    CANCER RESEARCH, 2006, 66 (08)
  • [2] Insulin-like growth factor-I receptor inhibition by specific tyrosine kinase inhibitor NVP-AEW541 in endometrioid and serous papillary endometrial cancer cell lines
    Attias-Geva, Zohar
    Bentov, Itay
    Fishman, Ami
    Werner, Haim
    Bruchim, Ilan
    GYNECOLOGIC ONCOLOGY, 2011, 121 (02) : 383 - 389
  • [3] The aromatase inhibitor letrozole and inhibitors of insulin-like growth factor I receptor synergistically induce apoptosis in in vitro models of estrogen-dependent breast cancer
    Lisztwan, Joanna
    Pornon, Astrid
    Chen, Bin
    Chen, Shiuan
    Evans, Dean B.
    BREAST CANCER RESEARCH, 2008, 10 (04)
  • [4] The aromatase inhibitor letrozole and inhibitors of insulin-like growth factor I receptor synergistically induce apoptosis in in vitro models of estrogen-dependent breast cancer
    Joanna Lisztwan
    Astrid Pornon
    Bin Chen
    Shiuan Chen
    Dean B Evans
    Breast Cancer Research, 10
  • [5] Co-targeting the EGFR and IGF-IR with anti-EGFR monoclonal antibody ICR62 and the IGF-IR tyrosine kinase inhibitor NVP-AEW541 in colorectal cancer cells
    Cunningham, Matthew P.
    Thomas, Hilary
    Marks, Christopher
    Green, Margaret
    Fan, Zhen
    Modjtahedi, Helmout
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2008, 33 (05) : 1107 - 1113
  • [6] Inhibition of insulin-like growth factor-I receptor (IGF-IR) using NVP-AEW541, a small molecule kinase inhibitor, reduces orthotopic pancreatic cancer growth and angiogenesis
    Moser, Christian
    Schachtschneider, Philipp
    Lang, Sven A.
    Gaumann, Andreas
    Mori, Akira
    Zimmermann, Johann
    Schlitt, Hans J.
    Geissler, Edward K.
    Stoeltzing, Oliver
    EUROPEAN JOURNAL OF CANCER, 2008, 44 (11) : 1577 - 1586
  • [7] Inhibition of insulin-like growth factor-I receptor using NVP-AEW541, a small molecule kinase inhibitor, reduces orthotopic pancreatic cancer growth and angiogenesis
    Moser, C.
    Schachtschneider, P.
    Lang, S. A.
    Schlitt, H. -J.
    Geissler, E. K.
    Kaufmann, B.
    Zimmermann, J.
    Stoeltzing, O.
    ONKOLOGIE, 2008, 31 : 83 - 83
  • [8] Insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 is active in breast cancer cells and enhances growth inhibition by herceptin through an increase in cell cycle arrest
    Esparis-Ogando, A.
    Rodriguez-Barrueco, R.
    Borges, J.
    Ferreira, L.
    Pandiella, A.
    Ocana, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [9] Sensitivity of breast cancer cell lines to the novel insulin-like growth factor-1 receptor (IGF-1R) inhibitor NVP-AEW541 is dependent on the level of IRS-1 expression
    Mukohara, Toru
    Shimada, Hiroyuki
    Ogasawara, Naomi
    Wanikawa, Ryoko
    Shimomura, Manami
    Nakatsura, Tetsuya
    Ishii, Genichiro
    Park, Joon Oh
    Jaenne, Pasi A.
    Saijo, Nagahiro
    Minami, Hironobu
    CANCER LETTERS, 2009, 282 (01) : 14 - 24
  • [10] Responses of human pancreatic cancer cells to treatment with insulin-like growth factor receptor (IGF-IR) tyrosine kinase inhibitor NVP-AEW541 alone and in combination with anti-EGFR mAb ICR62 or cytotoxic drugs
    Ioannou, Nikolaos
    Seddon, Alan M.
    Dalgleish, Angus
    Mackintosh, David
    Modjtahedi, Helmout
    CANCER RESEARCH, 2011, 71
12